Novo Nordisk | NVO - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
ANI Pharmaceuticals USD 311.18M 25.59M 2026-03
Aurora Cannabis CAD 56.36M 39.33M 2025-12
Bausch Health Companies USD 1.31B 1000K 2025-12
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Canopy Growth CAD 371.32M 73.26M 2025-12
Corcept Therapeutics USD 108.74M 11.76M 2026-03
Drreddys Laboratories INR 18.66B 9.65B 2025-12
Eli Lilly USD 5.28B 1.99B 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Merck USD 5.33B 9.24B 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Novartis USD 6.88B 4.56B 2026-03
Novo Nordisk DKK 38.94B 24.15B 2025-03
Novo Nordisk A/S DKK 18.44B 5.78B 2025-06
Pacira USD 144.31M 14.24M 2026-03
Perrigo USD 531.6M 99.5M 2025-12
Phibro Animal Health USD 54.93M 557K 2026-03
Prestige Brands USD 63.87M 1.5M 2026-03
Sanofi EUR 7.66B 1.25B 2025-12
Supernus Pharmaceuticals USD 184.87M 56.42M 2026-03
Zoetis USD 1.94B 369M 2026-03